Cargando…

No relation between docetaxel administration route and high‐grade diarrhea incidence

Oral administration of docetaxel in combination with the CYP3A4 inhibitor ritonavir is used in clinical trials to improve oral bioavailability of docetaxel. Diarrhea was the most commonly observed and dose‐limiting toxicity. This study combined preclinical and clinical data and investigated incidenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hendrikx, Jeroen J. M. A., Stuurman, Frederik E., Song, Ji‐Ying, de Weger, Vincent A., Lagas, Jurjen S., Rosing, Hilde, Beijnen, Jos H., Schinkel, Alfred H., Schellens, Jan H. M., Marchetti, Serena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387127/ https://www.ncbi.nlm.nih.gov/pubmed/32725720 http://dx.doi.org/10.1002/prp2.633

Ejemplares similares

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Protein versus DNA as a marker for peripheral blood mononuclear cell counting
por: Jansen, Robert S., et al.
Publicado: (2009)

Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours
por: Vermunt, Marit A. C., et al.
Publicado: (2021)

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment
por: van Andel, Lotte, et al.
Publicado: (2018)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
por: Vermunt, Marit, et al.
Publicado: (2021)

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
por: Vermunt, Marit A. C., et al.
Publicado: (2022)

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar()
por: Sawicki, Emilia, et al.
Publicado: (2016)

Phase I pharmacological study of continuous chronomodulated capecitabine treatment
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Pharmacokinetics and Excretion of (14)C-Bendamustine in Patients with Relapsed or Refractory Malignancy
por: Dubbelman, Anne-Charlotte, et al.
Publicado: (2013)

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
por: Loos, Nancy H. C., et al.
Publicado: (2022)

The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins
por: Loos, Nancy H.C., et al.
Publicado: (2023)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
por: Jager, N. G. L., et al.
Publicado: (2012)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx, Jeroen J M A, et al.
Publicado: (2020)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2019)

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis
por: Jacobs, Bart A.W., et al.
Publicado: (2019)

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability
por: Li, Wenlong, et al.
Publicado: (2021)

Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry
por: Susam, M. Merve, et al.
Publicado: (2022)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS
por: de Jong, Karen A.M., et al.
Publicado: (2021)

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism
por: Gan, Changpei, et al.
Publicado: (2023)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
por: Wang, Yaogeng, et al.
Publicado: (2021)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
por: Henricks, Linda M., et al.
Publicado: (2018)

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers
por: van den Broek, Irene, et al.
Publicado: (2010)

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
por: Kip, Anke E., et al.
Publicado: (2017)

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure
por: Wang, Jing, et al.
Publicado: (2022)

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling
por: Gast, Marie-Christine W, et al.
Publicado: (2008)

Treatment Individualization in Colorectal Cancer
por: van Geel, Robin M. J. M., et al.
Publicado: (2015)

Secondary Prophylaxis of Docetaxel Induced Diarrhea with Loperamide: Case Report
por: Lee, Hee Yeon, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0u6v3v9qfl8f801unrso67jbq1